Arm, Rambus among market cap stock movers on Tuesday
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Erasca Inc (ERAS)
The Erasca share price today is 9.990, view NASDAQ ERAS stock exchange data. Track the latest Erasca share price with real-time updates on ERAS stock performance including market cap, day range, 52-week range and dividend yield. Access ERAS charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.770
10.400
52 wk Range
1.060
24.280
Earnings results expected tomorrow
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.77010.400
52 wk Range
1.06024.280
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ERAS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
20.700
Upside
+107.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 20.700
(+107.21% Upside)
Earnings
Latest Release
12-03-2026
EPS / Forecast
-0.10 / -0.11
Revenue / Forecast
-- / --
Compare ERAS to Peers and Sector
Metrics to compare | ERAS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipERASPeersSector | |
|---|---|---|---|---|
P/E Ratio | −24.9x | −4.0x | −0.5x | |
PEG Ratio | −0.69 | −0.08 | 0.00 | |
Price/Book | 9.5x | 3.4x | 2.6x | |
Price / LTM Sales | - | 85.2x | 3.2x | |
Upside (Analyst Target) | 102.2% | 101.6% | 47.8% | |
Fair Value Upside | Unlock | −1.7% | 5.9% | Unlock |
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Erasca (ERAS) Share Price Today?
The Erasca share price today is 9.990.
What is the current Erasca (ERAS) share price and day range?
As of 06-05-2026, the Erasca share price is 9.990, with a previous close of 10.140. The share price has ranged from 9.770 to 10.400 today, while the 52-week range spans from 1.060 to 24.280.
What Is the Erasca Market Cap?
As of today, Erasca market cap is 3.100B.
What Is the Erasca (ERAS) Share Price Target?
The average 12-month share price target for Erasca is 20.700, with a high estimate of 30 and a low estimate of 9. 8 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +107.21% Upside potential.
What Is Erasca's Earnings Per Share (TTM)?
The Erasca EPS (TTM) is -0.439.
When Is the Next Erasca Earnings Date?
Erasca will release its next earnings report on 07-05-2026.
From a Technical Analysis Perspective, Is ERAS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Erasca Trade On?
Erasca is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Erasca?
The stock symbol for Erasca is "ERAS."
How Many Times Has Erasca Stock Split?
Erasca has split 0 times.
How Many Employees Does Erasca Have?
Erasca has 103 employees.
What Is the ERAS Premarket Price?
ERAS's last pre-market stock price is 10.310. The pre-market share volume is 14,750.000, and the stock has changed by 0.170, or 1.680%.
What Is the ERAS After Hours Price?
ERAS's last after hours stock price is 9.920, the stock has changed by -0.070, or -0.700%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.